Visit cardinalhealth.com

cardinal.com login

Username New user? Register Here

Password Forgot password?







View all results





View all results

About
How to Use
Case Studies
Contact Us
How to Order

About
How to Use
- - Dosing and Administration
  - Cardinal Health Nuclear & Precision Health Solutions Resources
Case Studies
Contact Us
How to Order

About

The first and only agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy,* LYMPHOSEEK provides accurate and precise lymph node identification in patients with solid tumors.

Mechanism of Action

Clinical Efficacy: Solid Tumors

How to Use

Review this section for more information on how to use LYMPHOSEEK in your patients to assist in the localization of lymph nodes draining a primary tumor site.

Dosing and Administration

Cardinal Health Nuclear & Precision Health Solutions Resources

Close menu

Home
About
Patents

alt

Patents

LYMPHOSEEK®:

U.S. Patent Nos.: 6,409,990; 8,545,808; 9,439,985. Other patents pending.

*Indication

LYMPHOSEEK is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.
Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

In clinical trials with LYMPHOSEEK, no serious hypersensitivity reactions were reported, however LYMPHOSEEK may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of LYMPHOSEEK, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).
Please see full Prescribing Information.

To report suspected adverse reactions, contact Cardinal Health at 1.800.618.2768 or FDA at 1.800.FDA.1088 or www.fda.gov/medwatch.

The information on this web site is intended for use only by healthcare professionals in the United States.

Lymphoseek

About
How to Use
Case Studies
Contact Us

Clinical Bibliography
Safety Profile
How to Order

Support

Privacy Policy
Terms and Conditions
Patent Information

Prescribing Information

©2019 Cardinal Health. All rights reserved.